114 related articles for article (PubMed ID: 9213469)
21. Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids.
Luo C; Johnston PJ; MacPhail SH; Banáth JP; Oloumi A; Olive PL
Exp Cell Res; 1998 Sep; 243(2):282-9. PubMed ID: 9743588
[TBL] [Abstract][Full Text] [Related]
22. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis is the most efficient death-pathway in tumor cells after topoisomerase II inhibition.
El-Awady RA; Ali MM; Saleh EM; Ghaleb FM
Saudi Med J; 2008 Apr; 29(4):558-64. PubMed ID: 18382799
[TBL] [Abstract][Full Text] [Related]
24. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
25. Experimental induction of apoptosis by a combination of etoposide and radiation treatment.
Toda H; Hasegawa M; Hayakawa K; Kawashima M; Nakamura Y; Yamakawa M; Mitsuhashi N; Niibe H
Anticancer Res; 2000; 20(1A):165-70. PubMed ID: 10769650
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
27. Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II.
Barret JM; Montaudon D; Etiévant C; Perrin D; Kruczynski A; Robert J; Hill BT
Anticancer Res; 2000; 20(6B):4557-62. PubMed ID: 11205304
[TBL] [Abstract][Full Text] [Related]
28. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.
Treszezamsky AD; Kachnic LA; Feng Z; Zhang J; Tokadjian C; Powell SN
Cancer Res; 2007 Aug; 67(15):7078-81. PubMed ID: 17671173
[TBL] [Abstract][Full Text] [Related]
29. [Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines].
Matsumoto Y; Morisaki K; Kunishio K; Nagao S; Takano H; Fojo T
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1145-9. PubMed ID: 9679576
[TBL] [Abstract][Full Text] [Related]
30. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
Pawlik CA; Israel M; Sweatman TW; Lothstein L
Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
[TBL] [Abstract][Full Text] [Related]
31. DNA topoisomerase II poisons and inhibitors.
Capranico G; Giaccone G; D'Incalci M
Cancer Chemother Biol Response Modif; 1999; 18():125-43. PubMed ID: 10800480
[No Abstract] [Full Text] [Related]
32. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
Karnaoukhova L; Moffat J; Martins H; Glickman B
Cancer Res; 1997 Oct; 57(19):4393-407. PubMed ID: 9331103
[TBL] [Abstract][Full Text] [Related]
33. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
34. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
[TBL] [Abstract][Full Text] [Related]
35. [Effect of oridonin on metabolism of thymine nucleotides in tumor cells in mice].
Li Y; Zhang TM
Zhongguo Yao Li Xue Bao; 1987 May; 8(3):271-4. PubMed ID: 2959027
[No Abstract] [Full Text] [Related]
36. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
Friche E; Danks MK; Beck WT
Cancer Res; 1992 Oct; 52(20):5701-6. PubMed ID: 1356619
[TBL] [Abstract][Full Text] [Related]
37. Re: Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
Liu WM; te Poele RH; Joel SP
J Natl Cancer Inst; 1998 Feb; 90(3):246-7. PubMed ID: 9462684
[No Abstract] [Full Text] [Related]
38. Synergistic effect of probimane on anticancer cytotoxicity of doxorubicin in vitro.
Zhang Y; Ye QX; Liu J; Zhang ZY; Zhang TM
Zhongguo Yao Li Xue Bao; 1994 Jan; 15(1):56-9. PubMed ID: 8010087
[TBL] [Abstract][Full Text] [Related]
39. Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin.
Pessina A; Raimondi A; Croera C; Acchini M; Mineo E; Foti P; Neri MG
Anticancer Drugs; 2001 Jun; 12(5):441-51. PubMed ID: 11395572
[TBL] [Abstract][Full Text] [Related]
40. Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288).
Lothstein L; Suttle DP; Roaten JB; Koseki Y; Israel M; Sweatman TW
Biochem Pharmacol; 2000 Dec; 60(11):1621-8. PubMed ID: 11077044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
